Should furosemide (Lasix) be held in a patient who experienced an episode of ventricular tachycardia (V-tach)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Furosemide should be temporarily held or used cautiously in a patient who experienced ventricular tachycardia (V-tach), especially if the patient has electrolyte abnormalities, such as hypokalemia or hypomagnesemia, which can be caused or exacerbated by furosemide and may trigger or worsen ventricular arrhythmias. This decision is based on the potential of furosemide to induce or exacerbate electrolyte imbalances, particularly hypokalemia, which is a known risk factor for ventricular arrhythmias 1.

Key Considerations

  • Before resuming furosemide, it is crucial to check and correct electrolyte levels, particularly potassium (aim for 4.0-5.0 mEq/L) and magnesium (aim for 2.0-2.5 mg/dL) 2, 1.
  • Assess the patient's volume status, as both hypovolemia and hypervolemia can contribute to cardiac instability.
  • If furosemide is necessary for volume management, consider using a lower dose with close monitoring of electrolytes, renal function, and cardiac rhythm.

Mechanism and Risks

Furosemide works as a loop diuretic by inhibiting sodium and chloride reabsorption in the ascending loop of Henle, which increases urinary excretion of sodium, chloride, potassium, and water, potentially leading to electrolyte imbalances that can predispose to cardiac arrhythmias. The use of furosemide has been associated with an increased risk of ventricular arrhythmias, particularly in patients with underlying heart disease or electrolyte imbalances 1, 3.

Recent Evidence

A study from 2004 found that furosemide accelerated the progression of left ventricular dysfunction in an experimental model of heart failure, highlighting the potential risks of furosemide in patients with heart failure 3. However, the most recent and relevant study to the question of ventricular tachycardia management is from 2023, which discusses the diagnosis and management of ventricular tachycardia but does not directly address the use of furosemide in this context 4.

Clinical Decision

Given the potential risks and the importance of maintaining electrolyte balance and cardiac stability, the decision to hold or resume furosemide should be made cautiously and on a case-by-case basis, prioritizing the correction of electrolyte imbalances and the assessment of the patient's volume status. If furosemide is deemed necessary, close monitoring of the patient's condition, including electrolyte levels and cardiac rhythm, is essential.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.